Tom E. Howard, MD, PhD, on a Gene Editing Approach to Treating Hemophilia A
The clinical professor in the Department of Human Genetics at University of Texas Rio Grande Valley discussed how a personalized gene editing approach may help patients avoid development of FVIII inhibitors.
This is the second part of an interview with Tom E. Howard, MD, PhD. For the first part,
“Our ultimate goal is to have a cell therapy that utilizes our gene editing-based therapeutic, to be able to get patients their own cells back making high enough levels of their own FVIII protein where they don't have to get treated again or maybe only have to get treated once every year or 2 years, instead of 3 times a week having to inject themselves with the protein...”
Currently, one of the main treatment options for patients with hemophilia A is receiving exogenous infusions of the disease-targeted protein, Factor VIII (FVIII), multiple times per week. Although this option is effective for some patients, other patients may develop an immune response to these exogenous proteins in the form of FVIII inhibitors, limiting their ability benefit from or continue to receive the treatment. Tom E. Howard, MD, PhD, a clinical professor in the Department of Human Genetics at University of Texas Rio Grande, and his colleagues, have been investigating this issue for many years, and recently presented some of their findings at the
CGTLive™ spoke with Howard at the conference to learn more. After discussing
REFERENCES
1. Bouls R, AlmeidaMA, DiegoVP, et al. Gene-centric association scans of pleiotropic immune-mediated disease genes in the PATH study identify novel determinants of Factor VIII inhibitor risk in hemophilia-A patients and confirm race as an independent predictor. Presented at: ASH 2023 Annual Meeting & Exposition. December 9-12; San Diego, CA. Abstract #1246
2. Ibarra P, Almeida MA, Diego VP, et al. Results from an association-scan of the extended MHC-Class-II region using novel association-based statistical methods establish that DQ allotypes and race independently influence the risk of factor VIII inhibitor development in hemophilia-A patients. Presented at: ASH 2023 Annual Meeting & Exposition. December 9-12; San Diego, CA. Abstract #1247
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- Duchenne Action Month 2025: Looking Back at News and Expert Insights
September 14th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025